Clinical Trial Update: Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients [Phase 2]

View source ↗

Summary

Phase 2 study of EI-001 for non-segmental vitiligo is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo

Drugs mentioned

• EI-001

Snippet

Sponsor: Elixiron Immunotherapeutics (Hong Kong) Ltd. | Conditions: Non-segmental Vitiligo | Phase 2 | Status: RECRUITING